Shots:

• The two companies collaborated to develop a COVID-19 vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. The partners are planning to initiate P-I study in mid-July followed by pre-clinical results that showed combining the two platforms demonstrated a high level of neutralizing Abs following a single dose
• The study will evaluate the safety and immunogenicity of three different dose levels of antigen combined with GSK’s adjuvant and compared it with adjuvant of another company- administered on a one- and two-dose vaccination schedule- given 21 days apart
• Medicago will leverage its plant-based production platform to manufacture the COVID-19 vaccine antigen by using the leaves of a plant as bioreactors to produce the S-spike protein which self-assembles into VLPs for use in the CoVLP vaccine candidate. The companies aim to complete the development and make it available in H1’21 and expect to manufacture ~100M doses by the end of 2021

Ref: GSK | Image: GSK